|Videos|June 21, 2023
Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific
Maria-Victoria Mateos, MD, PhD, presents the case of a 52-year-old patient with penta-exposed MM who receives treatment with a non-BCMA-targeting bispecific.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutant HR+/HER2– Breast Cancer
5